Internet Explorer 11 has been retired by Microsoft as of June 15, 2022. To get the best experience on this website, we recommend using a modern browser, such as Safari, Chrome or Edge.
Study for breast cancer that has spread to other parts of the body.
Trial ID:
IRB-22-8006
Mohammed Ali Jaloudi, MD
This study is evaluating an investigational combination treatment compared to current approved anti-cancer medications for ER-positive/HER2-negative breast cancer that has spread to parts of the body beyond the breast. There is no placebo in this clinical study. Everyone receives treatment with a combination of oral breast cancer medications taken once per day for each 28Day cycle. Study visits include health checks, tests, and questionnaires. All study visits will be scheduled at Scripps Clinic Torrey Pines or Scripps Clinic Encinitas.
*Be male or female age 18Yrs or older; AND<br><br>*Have estrogen receptor (ER)-positive/human epidermal growth factor (HER2)-negative cancer; AND<br><br>*Have been previously treated for breast cancer; AND<br><br>*Have cancer that has returned or worsened; AND<br><br>*Have cancer that has spread in a way that cannot be treated with surgery.